Abstract | PURPOSE: EXPERIMENTAL DESIGN: Patients with prostate cancer detectable by serum prostate-specific antigen (PSA) following radical prostatectomy received 3 to 4 months of androgen suppression therapy, and were then randomized (2:1) to receive sipuleucel-T (n = 117) or control (n = 59). The primary endpoint was time to biochemical failure (BF) defined as serum PSA ≥ 3.0 ng/mL. PSA doubling time (PSADT), time to distant failure, immune response, and safety were also evaluated. RESULTS: Median time to BF was 18.0 months for sipuleucel-T and 15.4 months for control (HR = 0.936, P = 0.737). Sipuleucel-T patients had a 48% increase in PSADT following testosterone recovery (155 vs. 105 days, P = 0.038). With only 16% of patients having developed distant failure, the treatment effect favored sipuleucel-T (HR = 0.728, P = 0.421). The most frequent adverse events in sipuleucel-T patients were fatigue, chills, and pyrexia. Immune responses to the immunizing antigen were greater in sipuleucel-T patients at Weeks 4 and 13 (P < 0.001, all) and were sustained prior to boosting as measured in a subset of patients a median of 22.6 months (range: 14.3-67.3 months) following randomization. CONCLUSIONS: No significant difference in time to BF could be shown. The finding of increased PSADT in the sipuleucel-T arm is consistent with its biologic activity in ADPC. Long-term follow-up will be necessary to determine if clinically important events, such as distant failure, are affected by therapy. Treatment was generally well tolerated.
|
Authors | Tomasz M Beer, Guy T Bernstein, John M Corman, L Michael Glode, Simon J Hall, Wayne L Poll, Paul F Schellhammer, Lori A Jones, Yi Xu, Jelle W Kylstra, Mark W Frohlich |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 17
Issue 13
Pg. 4558-67
(Jul 01 2011)
ISSN: 1557-3265 [Electronic] United States |
PMID | 21558406
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androgens
- Cancer Vaccines
- Tissue Extracts
- Intercellular Adhesion Molecule-1
- sipuleucel-T
- Prostate-Specific Antigen
|
Topics |
- Aged
- Androgens
(metabolism)
- Cancer Vaccines
(adverse effects, therapeutic use)
- Humans
- Immunotherapy, Adoptive
(adverse effects)
- Intercellular Adhesion Molecule-1
(immunology, metabolism)
- Male
- Middle Aged
- Prostate-Specific Antigen
(metabolism)
- Prostatic Neoplasms
(immunology, therapy)
- Tissue Extracts
(adverse effects, therapeutic use)
- Treatment Outcome
- Up-Regulation
(immunology)
|